LB Pharmaceuticals
LBRX · Nasdaq · United States
Share price · LBRX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when LBRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-6.3%
Nothing announced by LBRX that day or the session before.
- 6 Nov 2026+10.3%
- 5 Oct 2026-6.4%
Nothing announced by LBRX that day or the session before.
- 14 Aug 2026+7.9%
Nothing announced by LBRX that day or the session before.
- 3 Aug 2026+6.9%
Nothing announced by LBRX that day or the session before.
- 29 Jul 2026+11.6%
- 22 Jul 2026+10.9%
- 17 Jun 2026+8.6%
Nothing announced by LBRX that day or the session before.
- 15 Apr 2026+9.6%
Nothing announced by LBRX that day or the session before.
- 5 Feb 2026+12.7%
Share of unusual movement by asset
For each asset, the share of LBRX's own-move activity since 12 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Dopamine D2/D3 receptor + 5-HT7 receptorSmall molecule | Major Depressive DisorderSchizophrenia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (7)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $52M | $215M+ $189M short-term inv. | $59M-$64M operating cash flow | report ↗ |
View 6 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $44M | $283M+ $45M short-term inv. | $52M-$38M operating cash flow | report ↗ |
| 2026-Q1 | — | $15M | $321M+ $45M short-term inv. | $19M-$23M operating cash flow | report ↗ |
| 2025-Q3 | — | $2.4M | $270M+ $45M short-term inv. | $3.6M-$3.4M operating cash flow | report ↗ |
| 2025-Q2 | — | $2.4M | — | $4.9M-$5.6M operating cash flow | report ↗ |
| 2025-Q1 | — | $3.4M | — | $5.3M-$8.1M operating cash flow | report ↗ |
| 2024-Q3 | — | $11M | — | $14M | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $17M | $250M+ $45M short-term inv. | $6.3M-$35M operating cash flow | report ↗ |
LB Pharmaceuticals reported R&D spend of $16.74M, down 67.3% YoY, cash and equivalents of $250.17M, and a net loss of $25.2M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $51M | $23M+ $5.0M short-term inv. | $16M-$53M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-09 | Miller Joseph M · Chief Financial Officer | Award / grant (derivative) | 200,000 | — | — | Form 4 |
| 2026-10-09 | Kozauer Susan Gani · Chief Medical Officer | Award / grant (derivative) | 200,000 | — | — | Form 4 |
| 2026-07-30 | Deep Track Biotechnology Master Fund, Ltd.; Deep Track Capital, LP; KROIN DAVID · 10% owner; 10% owner; 10% owner | Open-market purchase (derivative) | 286,205 | $34.94 | $10.0M | Form 4 |
| 2026-06-03 | Garland J. Scott · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-06-03 | Kane William P Jr · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-06-03 | Hemrajani Rekha · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-06-03 | Lenz Robert A. · director | Award / grant (derivative) | 12,500 | — | — | Form 4 |
| 2026-06-03 | Luse Rebecca · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 77 reporting institutions held 28.3M shares ($693.3M, 98.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Deep Track Capital, LP | 3,352,804 | $82.7M |
| 2 | BlackRock, Inc. | 2,470,845 | $60.9M |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 2,208,604 | $54.5M |
| 4 | TCG Crossover Management, LLC | 1,839,489 | $45.3M |
| 5 | Commodore Capital LP | 1,500,000 | $37.0M |
| 6 | Caligan Partners LP | 1,438,070 | $34.6M |
| 7 | Spruce Street Capital LP | 1,376,159 | $33.6M |
| 8 | JPMORGAN CHASE & CO | 1,427,568 | $33.2M |
| 9 | Trails Edge Capital Partners, LP | 1,319,362 | $32.5M |
| 10 | Nantahala Capital Management, LLC | 1,052,894 | $26.0M |
| 11 | Balyasny Asset Management L.P. | 923,694 | $22.8M |
| 12 | Logos Global Management LP | 915,000 | $22.6M |
| 13 | VANGUARD CAPITAL MANAGEMENT LLC | 894,653 | $22.1M |
| 14 | Alyeska Investment Group, L.P. | 863,947 | $21.3M |
| 15 | Vivo Capital, LLC | 800,000 | $19.7M |